To homepage

Page 2 - Best Uterine cancer doctors: TOP 77 doctors

Content meets the Bookimed Editorial Policy and is medically reviewed by

Fahad Mawlood

Saban Sec

  • 4.9 Excellent 53 reviews
  • 13 years of experience
  • Turkey, Istanbul, Valued Med Hub Hospitals
  • Specialist in urogenital cancers with a focus on research-backed treatments – Dr. Sec serves as the Turkish Medical Oncology Association's Specialist Physicians Representative.

    • Over 5 years of experience in medical oncology
    • Published multiple studies on cancer treatment outcomes
    • Member of Turkish Medical Oncology Association
    • Works at Bahçelievler Medikalpark Hospital
  • Read more
Hysterectomy (uterus removal)
$15,000 - $15,000
Laparoscopic Hysterectomy
$8,000 - $10,000
Info

Tahsin Ozadli

  • 4.9 Excellent 53 reviews
  • 22 years of experience
  • Turkey, Istanbul, Valued Med Hub Hospitals
  • Education and Expertise

    Selcuk University Meram Faculty of Medicine - Medical Education

    Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

     

    Experience

    Malatya State Hospital Internal Diseases Clinic

    Ankara Oncology Hospital Medical Oncology Clinic

    Erzurum Regional Training and Research Hospital Medical Oncology Clinic


    AREAS OF INTEREST

    Lung cancer

    esophageal cancer

    Gastric cancer

    breast cancer

    Gastrointestinal surgery

    https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

  • Read more
Hysterectomy (uterus removal)
$15,000 - $15,000
Laparoscopic Hysterectomy
$8,000 - $10,000
Info

Turkan Ozturk Topcu

  • 4.9 Excellent 53 reviews
  • 17 years of experience
  • Turkey, Istanbul, Valued Med Hub Hospitals
  • Dr. Topcu specializes in uterine cancer treatment with extensive international training at top cancer centers like MD Anderson and Moffit.

    • Medical oncology specialist with 15+ years of experience
    • Trained at MD Anderson Cancer Center and Sunnybrook Odette Cancer Center
    • Expert in gynecological cancers including uterine and ovarian
    • Works at Valued Med Hub Hospitals
  • Read more
Hysterectomy (uterus removal)
$15,000 - $15,000
Laparoscopic Hysterectomy
$8,000 - $10,000
Info

Wolfgang Köstler

  • 4.7 Excellent 153 reviews
  • 21 years of experience
  • Austria, Vienna, Wiener Privatklinik
  • Univ. Prof. Dr. Wolfgang Köstler is a leading oncologist specializing in gynecologic cancers, with over 20 years of experience at Wiener Privatklinik.

    • Expert in targeted therapies for uterine cancer
    • Deputy Head of Clinical Division of Oncology at Medical University of Vienna
    • Published researcher in biomarker development and tumor biology
    • Focuses on individualized systemic cancer therapy and immunotherapy
  • Read more
Doctor's visit
Price on request
Info

Ercan Ozden

  • 5 Excellent 1 review
  • 26 years of experience
  • Turkey, Istanbul, VM Medical Park Pendik Hospital
  • Dr. Ozden brings over 20 years of medical experience, specializing in oncology with a focus on uterine cancer at VM Medical Park Pendik Hospital.

    • Graduated from Istanbul University's prestigious Cerrahpaşa Faculty of Medicine
    • Completed Medical Oncology subspecialty at Kocaeli University
    • Extensive experience in both public and private hospital settings
    • Practiced internal medicine before specializing in oncology
  • Read more
Doctor's visit
Price on request
Info

Tahsin Ozatli

  • 4.4 Good 17 reviews
  • 2015 years of experience
  • Turkey, Istanbul, Istinye University Liv Hospital Bahcesehir
  • Associate Professor Tahsin Ozatli specializes in breast, lung, and gastrointestinal cancers at Istinye Liv University Hospital.

    • Over 10 years of experience in oncology
    • Trained at Selcuk University's Faculty of Medicine
    • Previously worked at Ankara Oncology Clinic
    • Promoted to Associate Professor in 2016
  • Read more
Chemotherapy for uterine cancer
$2,000 - $8,000
Hysterectomy (uterus removal)
$15,000 - $15,000
Info

Nail Paksoy

  • 4.5 Good 2 reviews
  • 14 years of experience
  • accreditation:
  • Turkey, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Read more
Radiotherapy for uterine cancer
$4,000 - $6,000
Laparoscopic Hysterectomy
$5,000 - $5,000
Hysterectomy (uterus removal)
$5,000 - $5,000
Info

Seyda Gunduz

  • 4.4 Good 17 reviews
  • 15 years of experience
  • Turkey, Istanbul, Istinye University Liv Hospital Bahcesehir
Chemotherapy for uterine cancer
$2,000 - $8,000
Hysterectomy (uterus removal)
$15,000 - $15,000
Info

Serap Kaya

  • 4.4 Good 32 reviews
  • 25 years of experience
  • Turkey, Istanbul, Emsey Hospital
  • Assoc. Prof. Serap Kaya specializes in uterine cancer treatment with extensive experience in medical oncology.

    • Trained at Marmara University Faculty of Medicine
    • Specialized at Kartal Dr. Lütfi Kırdar Training and Research Hospital
    • Minor in Medical Oncology from Kocaeli University
    • Worked at Marmara University Pendik Training and Research Hospital
  • Read more
Radiotherapy for uterine cancer
$8,500 - $16,000
Chemotherapy for uterine cancer
$1,500 - $5,000
Info

Sridhar P.S.

  • New
  • 29 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
  • Dr. Sridhar P.S. specializes in radiotherapy for uterine cancer with extensive training from top Indian universities.

    • Diplomate of National Board in radiotherapy
    • Member of Association of Radiation Oncology of India
    • Part of the Bangalore Oncology Group
    • Specializes in hyperthermia oncology techniques
  • Read more
Hysterectomy (uterus removal)
$4,200 - $5,000
Laparoscopic Hysterectomy
$4,000 - $6,000
Info

Chaitainya Borde

  • New
  • 10 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
  • Dr. Chaitainya Borde has handled over 30,000 PET scans and treated 1,000+ thyroid cancer patients at HCG Manavata Cancer Centre.

    • 12 years of experience in nuclear medicine
    • Expert in PET-CT scans and nuclear cardiology services
    • Specializes in radioiodine and Lu-177 RN therapies
    • Published research in medical journals
  • Read more
Hysterectomy (uterus removal)
$4,200 - $5,000
Laparoscopic Hysterectomy
$4,000 - $6,000
Info

Ravindra Tandale

  • New
  • 16 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
Hysterectomy (uterus removal)
$4,200 - $5,000
Laparoscopic Hysterectomy
$4,000 - $6,000
Info

Shruti Kate

  • New
  • 14 years of experience
  • India, Nashik, HCG Manavata Cancer Centre
  • Dr. Shruti Kate specializes in gynecological cancers with deep expertise in immunotherapy and metronomic therapy for advanced cases. She trained at Tata Memorial Hospital – one of India's top cancer centers.

    • DM in Medical Oncology from Tata Memorial Hospital
    • Member of ASCO, ESMO, and other leading oncology societies
    • Presented lung cancer research at World Conference on Lung Cancer
    • Special focus on breast and gynecological cancers
  • Read more
Hysterectomy (uterus removal)
$4,200 - $5,000
Laparoscopic Hysterectomy
$4,000 - $6,000
Info

Shaunak Valame

  • New
  • 9 years of experience
  • accreditation:
  • India, Nashik, HCG Manavata Cancer Centre
  • Dr. Shaunak specializes in uterine cancer with expertise in targeted therapies and molecular oncology. His research on stomach cancer was presented at the elite ASCO Gastrointestinal Cancer Symposium.

    • Completed DNB in Medical Oncology from Indraprastha Apollo Hospital
    • Former Registrar in Medical Oncology at Jawaharlal Nehru Cancer Hospital
    • Delivered lectures at International Winter School of Oncology
    • Senior Residency in Internal Medicine from Shyam Shah Medical College
  • Read more
Hysterectomy (uterus removal)
$4,200 - $5,000
Laparoscopic Hysterectomy
$4,000 - $6,000
Info

Sarat Chandra P

  • 4.7 Excellent 3 reviews
  • India, Bengaluru, Manipal Hospitals
  • Dr. Sarat Chandra P is a dedicated oncologist at Manipal Hospitals, bringing specialized expertise to uterine cancer care.

    • Focused practice in oncology
    • Affiliated with a leading healthcare institution
    • Committed to evidence-based treatment approaches
  • Read more
Brachytherapy for uterine cancer
$2,000 - $2,000
Info

Sebastian Keil

  • 4.7 Excellent 60 reviews
  • 21 years of experience
  • Germany, Solingen, Medical Center in Solingen
  • Professor Keil specializes in advanced imaging techniques for uterine cancer, leveraging his extensive training at top German hospitals.

    • Graduated with honors from Julius-Maximilians-Universität Würzburg
    • Expert in MRI, CT, and ultrasound for complex interventions
    • Chief Physician at Academic Hospital Solingen since 2022
    • Former leading doctor at University Hospital of Aachen
  • Read more
Brachytherapy for uterine cancer
$5,892.16 - $8,838.24
Info

Agoritsa Stergiou-Tsaroucha

  • 4.6 Excellent 129 reviews
  • Germany, Hamburg, Asklepios Hospital Barmbek
  • Specialist in minimally invasive surgery for uterine cancer – Dr. Stergiou-Tsaroucha focuses on preserving reproductive health while ensuring effective treatment.

    • Expert in hysterectomy procedures
    • Treats uterine myomas and ovarian diseases
    • Provides care for prolapse of pelvic organs
  • Read more
Radiotherapy for uterine cancer
$9,427.46 - $15,319.62
Hysterectomy (uterus removal)
$21,211.78 - $25,925.51
Info

Kim Young Tae

  • 4.6 Excellent 42 reviews
  • Republic of Korea, Seoul, Severance Hospital
  • Specialist in robotic surgery – Dr. Kim Young Tae at Severance Hospital brings precision to uterine cancer treatment.

    • Oncogynecologist with a focus on uterine cancer
    • Uses robotic surgery for minimally invasive procedures
    • Practices at Severance Hospital
  • Read more
Radiotherapy for uterine cancer
$17,000 - $18,000
Info

Kim Sung Hun

  • 4.6 Excellent 42 reviews
  • Republic of Korea, Seoul, Severance Hospital
  • Oncogynecologist specializing in minimally invasive surgeries for uterine cancer at Severance Hospital.

    • Expert in advanced laparoscopic and robotic techniques
    • Focuses on preserving fertility when possible
    • Works at one of Korea's leading cancer centers
  • Read more
Radiotherapy for uterine cancer
$17,000 - $18,000
Info

Rafael Katan

  • 5 Excellent 2 reviews
  • Israel, Ramat Gan, Sheba Medical Center
  • Professor and Head of the Oncology Center at Sheba Medical Center – leading expert in uterine cancer treatment.

    • Extensive experience in managing complex uterine cancer cases
    • Holds a leadership role at a top-tier medical institution
    • Focuses on providing personalized treatment plans
  • Read more
Doctor's visit
Price on request
Info

Bookimed Insights: Top Doctors for Uterine cancer Treatment

Bookimed has coordinated 548 patient requests for Uterine cancer treatment, working with 77 specialists worldwide. The doctors in this table consistently stand out for their credentials and expertise in addressing specific patient needs. All information comes from actual patient cases and treatment offers created by our partner clinics.
DoctorexperienceGood Fit ForWhat Sets Them ApartClinic & LocationConsultation
13 years of experienceUrogenital cancersFocuses on urogenital cancers with research-backed approaches. Representative for Turkish Medical Oncology Association with multiple published studies.
Turkey
Price on request
17 years of experienceGynecological cancersSpecializes in uterine cancer with training at MD Anderson. Experienced in treating various gynecological cancers. Medical oncology specialist with international exposure.
Turkey
Price on request
21 years of experienceTargeted therapy casesSpecializes in precision oncology for gynecologic malignancies. Deputy Head of Clinical Division of Oncology at Medical University of Vienna with extensive research in biomarker development.
Austria
Price on request
26 years of experienceUterine cancer casesSpecialized in Medical Oncology with subspecialty training. Works at a leading hospital with comprehensive cancer treatment facilities.
Turkey
Price on request
2015 years of experienceBreast, lung, and gastrointestinal cancersSpecializes in multiple major cancer types with academic recognition. Associate Professor with extensive hospital experience.
Turkey
Price on request
25 years of experienceMedical oncology casesSpecializes in uterine cancer with a minor in Medical Oncology. Works at Emsey Hospital with extensive training and research background.
Turkey
from $110
29 years of experienceRadiotherapy for uterine cancerSpecializes in radiotherapy with advanced training and membership in key oncology societies, including hyperthermia oncology.
India
Price on request
10 years of experienceThyroid cancer diagnosticsExtensive imaging expertise – performed 30,000+ PET scans. Specializes in radioiodine therapies and Lu-177 treatments for thyroid cancer.
India
Price on request
14 years of experienceAdvanced gynecological cancersFocuses on immunotherapy and metronomic therapy for complex cases. Trained at Tata Memorial Hospital – among India's top cancer centers. ASCO & ESMO member.
India
Price on request
9 years of experienceTargeted therapiesSpecializes in molecular oncology and targeted therapies. Presented research at ASCO Gastrointestinal Cancer Symposium. DNB from Indraprastha Apollo Hospital.
India
Price on request